Free signup for more
- Track your favorite companies
- Receive email alerts for new filings
- Personalized dashboard of news and more
- Access all data and search results
Filing tables
Filing exhibits
- S-4 Registration of securities issued in business combination transactions
- 3.3 EX-3.3
- 3.4 EX-3.4
- 10.55 EX-10.55
- 10.56 EX-10.56
- 10.57 EX-10.57
- 10.58 EX-10.58
- 23.1 EX-23.1
- 23.2 EX-23.2
- 99.5 EX-99.5
- 99.6 EX-99.6
- 99.7 EX-99.7
- 99.8 EX-99.8
- 99.9 EX-99.9
- EX-FILING FEES Calculation of Filing Fee Tables
- Download Excel data file
- View Excel data file
Associated filings
- 14 Feb 24 424B3 Prospectus supplement
- 14 Feb 24 EFFECT Notice of effectiveness
- 1 Feb 24 UPLOAD Letter from SEC
- 16 Jan 24 S-4/A Registration of securities issued in business combination transactions (amended)
-
14 Nov 23 S-4 Registration of securities issued in business combination transactions
SER similar filings
Filing view
External links
Exhibit 99.9
Consent to be Named as a Director
In connection with the filing by AgeX Therapeutics, Inc. (the “Company”) of the Registration Statement on Form S-4 and on Form S-1 with the Securities and Exchange Commission under the Securities Act of 1933, as amended (the “Securities Act”), I hereby consent, pursuant to Rule 438 of the Securities Act, to being named in the Registration Statement and any and all amendments and supplements thereto as a member of the board of directors of the Company following the consummation of the business combination. I also consent to the filing of this consent as an exhibit to such Registration Statement and any amendments thereto.
| Dated: November 7, 2023 | ||
| By: | /s/ Richard Marshall | |
| Name: | Richard Marshall | |